Drugs / MCO-010
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04945772 | Jul 2021 → Feb 2023 | hereditary neuro-ophthalmological disease, retinitis, retinitis pigmentosa | Nanoscope Therapeutics Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MCO-010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04945772 ↗ |
| Known as | Multi-Characteristic Opsin | “The purpose of the study is to evaluate the safety and efficacy of a single intravitreal injection of virally-carried Multi-Characteristic Opsin (MCO-010).” NCT04945772 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “The MCO-010 is an adeno-associated virus serotype 2-based vector carried multi-characteristic opsin (MCO) gene expression cassette” NCT04945772 ↗ |
| Route | Intravitreal | “single intravitreal injection” NCT04945772 ↗ |